期刊： LEUKEMIA & LYMPHOMA, 2022; 63 (1)
Acute myeloid leukemia (AML) with t(8;21) is a heterogeneous disease and needs to be stratified. Both, cancer cells and immune cells participate in tu......
期刊： LEUKEMIA & LYMPHOMA, 2022; 63 (2)
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has led to unprecedented results to date in relapsed/refractory (R/R) diffuse large B-cell ly......
期刊： LEUKEMIA & LYMPHOMA, 2022; 63 (2)
We investigated trends of survival in a population-based cohort study of all 181 adults who received HCT for ALL in Denmark between 2000-2019. Patient......
期刊： LEUKEMIA & LYMPHOMA, 2022; 63 (4)
SOCS-2 gene expression at diagnosis has been suggested as a predictor of clinical outcome in chronic myeloid leukemia (CML). In this study SOCS-2 and ......
期刊： LEUKEMIA & LYMPHOMA, 2022; 63 (6)
In this study, oxidative stress marker (malondialdehyde, MDA) and antioxidant enzymes (glutathione (GSH), catalase (CAT)) levels in the liver and panc......
期刊： LEUKEMIA & LYMPHOMA, 2022; 63 (7)
The phase 1b multicohort KEYNOTE-013 study assessed the safety and antitumor activity of pembrolizumab given at 10 mg/kg/day every 2 weeks for up to 2......
期刊： LEUKEMIA & LYMPHOMA, 2022; 63 (9)
We report on long-term outcomes of 267 patients (pts) with chronic myeloid leukemia (CML) treated with imatinib administered as initial therapy. The m......
期刊： LEUKEMIA & LYMPHOMA, 2022; 63 (10)
Identifying risk factors for intensive care unit (ICU) admission in acute leukemia (AL) patients may guide decision-making and improve prognosis. We i......
